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Edited by Masayuki MiyasakaAbstract S100A8, S100A9 and S100A12 proteins are associ-
ated with inﬂammation and tissue remodelling, both processes
known to be associated with high protease activity. Here, we re-
port that homo-oligomeric forms of S100A8 and S100A9 are
readily degraded by proteases, but that the preferred hetero-oligo-
meric S100A8/A9 complex displays a high resistance even
against proteinase K degradation. S100A12 is not as protease
resistant as the S100A8/A9 complex. Since speciﬁc functions
have been assigned to the homo- and heterooligomeric forms of
the S100A8 and A9 proteins, this ﬁnding may point to a post-
translational level of regulation of the various functions of these
proteins in inﬂammation and tissue remodelling.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Three members of the Ca2+-binding S100 family, S100A8,
S100A9, and S100A12, are predominantly expressed in mye-
loid and epithelial cells. They are well-known as inﬂammatory
marker proteins since elevated serum levels of these proteins
are found in patients suﬀering from a number of diseases such
as rheumatoid arthritis, cystic ﬁbrosis and some other inﬂam-
matory diseases [1–4]. S100A12, which is as S100A8 and A9 re-
leased from activated phagocytes, directly activates endothelial
cells, mononuclear phagocytes and lymphocytes through inter-
action with the receptor for advanced glycation end products
(RAGE) [5]. S100A8 and S100A9 form hetero and homo-oligo-
meric protein complexes [6]. Recent reports suggest that the
homo-oligomeric as well as the hetero-oligomeric protein com-
plexes may play distinct roles in cell physiology. The hetero-
oligomeric S100A8/A9 have been reported to induce neutro-
phil chemotaxis [7], to mediate apoptosis [8], to activate the
NFjB pathway [9], to exhibit antimicrobial activity by chelat-
ing divalent cations [10] and to modulate NADPH oxidase
activity by its property to bind arachidonic acid [11].
S100A8, but not S100A9, is (1) known as an essential molecule
in early embryogenesis [12], is (2) upregulated by UV light in
keratinocytes [13] and is (3) supposed to act as a regulator of
the telomerase in HaCat cells [14]. On the other hand,*Corresponding author. Fax: +49 (0) 251 8356549.
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binds to heparansulfate [16], (3) mediates neutrophil adhesion
to ﬁbronectin [17] and (4) displays mitogenic activity [18].
At sites of inﬂammation both S100A8 and A9 proteins as
well as various proteases are present in high concentrations.
We speculated that the various functions of the S100 hetero-
and homo-oligomers may be regulated by their diﬀerential pro-
tease sensitivity. Here, we report that the hetero-oligomeric
complex is in contrast to the homo-oligomeric proteins highly
protease resistant.2. Materials and methods
2.1. Preparation of granulocyte lysates
Buﬀy-coat granulocytes were isolated following standard protocols
[19]. Brieﬂy, the whole blood sample was diluted with complete spinner
medium and overlaid on a Biocoll cushion (1.077 mg/ml). After centri-
fugation the erythrocytes in the cell pellet were lysed in ice cold water.
After another centrifugation step the remaining granulocytes were
washed with TBS and subsequently lysed by soniﬁcation. The crude
lysate was centrifuged (10000 · g; 30 min, 4 C) and the cleared lysate
was frozen in aliquots.
2.2. Generation of recombinant proteins
S100 cDNAs were cloned into pQE32 (Qiagen) following standard
protocols and expressed as His-tagged proteins. Puriﬁcation of the re-
combinant proteins was performed following the manufacturer’s pro-
tocol. Brieﬂy, the bacterial cell pellet was solubilised in denaturing
lysis buﬀer containing 6 M guanidinium hydrochloride. The cleared
lysate containing the denatured proteins was incubated with chelating
NTA agarose (Qiagen, Du¨sseldorf) and subsequently proteins were
renatured by washing the column with buﬀers containing decreasing
concentrations of urea. After elution with imidazole containing non-
denaturing buﬀer, imidazole was removed by a gel ﬁltration chroma-
tography using PD-10 columns (Bio-Rad, Mu¨nchen).2.3. Protease resistance assay
Granulocyte lysate (10 lg) was incubated in 20 ll TBS (10 mM Tris;
150 mM NaCl, pH 7.4) or TBS; 1% SDS for 15 min with either trypsin
or proteinase K (40 lg) at 37 C or 55 C as indicated. Protease con-
centration was diluted 1:3 per step. Subsequently, loading buﬀer was
added and the samples were heated at 95 C to inactivate the protease
and denature the proteins. Finally, aliquots were subjected to gel elec-
trophoresis and proteins were visualised by Coomassie blue staining.
In parallel, S100 proteins were detected by Western blotting using
polyclonal S100A8-, S100A9- and S100A12-speciﬁc antibodies. An-
nexin A6 was detected using a monoclonal Annexin A6-speciﬁc anti-
body (Santa Cruz Biotechnology, CA). Western blot was performed
using a secondary antibody coupled with horseradish peroxidase and
by incubating the blot with a chemiluminescent reagent (ECL, Amer-
sham-Pharmacia).
Recombinant His-tagged S100 proteins (4 lg) were digested similar
to the granulocyte lysate except that 100 lg BSA was included in the
reaction mixture. After electrophoresis the upper part of the gel wasblished by Elsevier B.V. All rights reserved.
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nant S100 proteins a Western blot analysis was performed.S100A9
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Fig. 2. Treatment of granulocytic lysate with proteinase K. Granulo-
cytic lysate (10 lg protein) was incubated with decreasing amounts of
proteinase K (max. 40 lg) in 20 ll TBS; 1% SDS for 15 min at 37 C.
Aliquots were subjected to SDS–PAGE, and proteins were either
stained with Coomassie blue (upper panel) or probed with S100A8-,
S100A9 and S100A12-speciﬁc antibodies (lower panel) ‘‘C’’ represents
the undigested control. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this
article.)
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The S100 proteins S100A8, S100A9 and S100A12 are se-
creted from activated phagocytes at sites of inﬂammation [1],
where a high proteolytic activity is present. Distinct functions
are ascribed to the homo- and hetero-oligomeric complexes of
these S100 proteins [7–18]. In search for an evidence for a po-
tential posttranslational regulation of the S100 protein func-
tions via a diﬀerential stability against protease attack we
investigated the sensitivity of the diﬀerent complexes against
proteases.
All three S100 proteins are strongly expressed in granulo-
cytes [1]. Therefore, initially a granulocytic lysate was incu-
bated with diﬀerent concentrations of trypsin for 15 min at
37 C followed either by Coomassie blue staining or Western
blot analysis. As internal control the ubiquitously expressed
calcium-binding protein annexin A6 was used. Whereas annex-
in A6 is readily degraded by trypsin, both S100A8 and S100A9
are resistant against trypsin digestion over the entire concen-
tration range used (Fig. 1). The S100A8 seems to be reduced
in size by increasing trypsin concentration suggesting a partial
sensitivity of the S100A8 termini to trypsin.
Next, analogous experiments were performed using the
much more aggressive proteinase K (Fig. 2). Even under the
most aggressive conditions (1% SDS and 55 C incubation
temperature) and using high proteinase K concentrations of
2 mg/ml, both proteins are detectable by Western blotting.
The S100 proteins are known to change their conformation
upon binding to divalent cations. Saturation of the calcium
and zinc binding sites of S100A8/A9 does neither decrease
nor increase the protein resistance (Fig. 3). The simultaneouslyAnxA6
S100A9
S100A8
Trypsin conc.
trypsin
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Fig. 1. Treatment of granulocytic lysate with trypsin. Granulocytic
lysate (10 lg protein) was incubated with decreasing amounts of
trypsin (max. 40 lg, 1:3 diluted per step) in 20 ll TBS for 15 min at
37 C. Aliquots were subjected to a 15% SDS–PAGE and proteins
were stained Coomassie blue (upper panel). In parallel, Western blot
analysis was performed using S100A8-, S100A9- (middle panel), and
annexin A6- (lower panel) speciﬁc antibodies. ‘‘C’’ represents the
undigested control. Bands originating from trypsin are marked by
arrows. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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Fig. 3. Treatment of granulocytic lysate with proteinase K after
saturation of the of Zn2+ and Ca2+ binding sites. Granulocytic lysate
(10 lg protein) was incubated with decreasing amounts of proteinase
K (max. 40 lg, lane 2) in 20 ll TBS; 1% SDS for 15 min at 55 C. To
saturate the calcium and zinc binding sites of the S100 proteins ZnCl2
and CaCl2 (100 lM each) were added (lower panel). Aliquots were
subjected to SDS–PAGE, and proteins were probed with S100A9
speciﬁc antibodies. ‘‘C’’ represents the undigested control. High
concentrations of the S100 antigen result in a partial crossreaction of
the anti S100A9 antibody and S100A8 antibody with S100A8 and
S100A9, respectively resulting in weak extra bands.performed protein staining with Coomassie blue conﬁrms that
almost all of the granulocytic proteins are completely degraded
under these conditions as expected (Fig. 2).
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Fig. 4. Treatment of recombinant S100 proteins with proteinase K.
Individual recombinant hisS100A8 and hisS100A9 (4 lg each) were
incubated in the presence of BSA (100 lg) with proteinase K in TBS;
1% SDS at 55 C as described. The upper part of SDS–PAGE was
stained with Coomassie blue (upper panel), and the lower part was
blotted and probed with S100A8-, S100A9- and S100A12 (lower panel)
speciﬁc antibody. ‘‘C’’ represents the undigested control. The relatively
high antigen concentration result in a partial crossreaction of the anti
S100A9 antibody with S100A8 and vice versa. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
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myeloid cells, is also speciﬁcally released upon cellular activa-
tion. Treatment of granulocytic lysate with proteinase K fol-
lowed by Western blot analysis with S100A12-speciﬁc
antibodies reveals that S100A12 is not as protease resistant
as the S100A8/A9 complex (Fig. 2), but it seems to be more
resistant to proteinase K than the individual S100A8 or
S100A9 proteins (Fig. 4).
To analyse, whether both the hetero and the homo-oligo-
meric complexes of S100A8 and S100A9 are equally protease
resistant, we repeated the experiments using recombinant his-
tagged proteins. When hisS100A8 and hisS100A9 are individ-
ually incubated with proteinase K in TBS; 1% SDS at 55 CAnti S100A8
A8/A
A8+A
C
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Fig. 5. Treatment of recombinant S100 proteins with proteinase K after olig
incubated for 1 h at 4 C prior to the treatment with proteinase K (left pan
renatured prior to the treatment with proteinase K (right panel). A 15% SDS
indicated. The relatively high antigen concentration result in a partial crossrboth recombinant proteins are readily digested similar to
BSA used as control (Fig. 4).
Similar results are obtained when the individually puriﬁed
and renatured recombinant proteins are mixed and incubated
for 1 h at 4 C prior to proteinase K treatment (Fig. 5, left
panel). In contrast, if the mixed recombinant proteins have
been denatured and renatured to enable proper complex
formation prior to proteinase K treatment the hisS100A8/
hisS100A9 complex is resistant to proteinase K treatment
(Fig. 5, right panel). These data indicate that proteinase K
resistance is largely dependent on proper formation of the
S100A8/A9 hetero-oligomeric protein complex. Using the re-
combinant proteins a denaturing–renaturing cycle is essential
for the formation of a stable native-like S100A8/A9 complex
conﬁrming a recent report of Leukert et al. [20]. The low pro-
tease resistance of the S100 homo-oligomers might also explain
the absence of S100A8 protein in granulocytes of the S100A9
deﬁcient mouse although S100A8 mRNA is abundantly pres-
ent in wild type as well as in deﬁcient granulocytes [21,22]. This
ﬁnding sustains the hypothesis that at least in S100A9/
granulocytes S100A8 protein is posttranslationally degraded
because of the absence of its interaction partner S100A9.
Matrix metalloproteases are associated with inﬂammatory
processes and tissue remodelling. S100A8/A9 is involved in
the transcriptional regulation of matrix metalloprotease
(MMP) activity [23]. Additionally, Isaksen and Fagerhol [24]
reported that S100A8/A9 inhibits MMP by sequestration of
zinc ions. A high stability against protease attack is certainly
a prereqisite for any protease inhibitor. This is in contrast to
another observation, in which S100A8 and S100A9 were iden-
tiﬁed as substrates of MMP2 and MMP9, suggesting that deg-
radation of the S100 proteins may abrogate their chemotactic
eﬀect and thus resolve an inﬂammation [25]. Nonetheless, it is
worthwhile mentioning that MMPs not only degrade extracel-
lular matrix proteins but also activates a broad range of cyto-
kines, including interleukin 1, tumour necrosis factor-a, Fas
ligand, and transforming growth factor-a, and thereby play
important roles in regulating processes such as acute and
chronic inﬂammation, tumour cell invasion, apoptosis, and
macrophage chemotaxis [26]. Thus, at least some of the pleio-
tropic functions of the extracellular S100A8/A9 complex may
be attributed to the inhibiting eﬀect on the MMPs.9
9
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omerisation. Recombinant hisS100A8 and hisS100A9 were mixed and
el). In parallel, the recombinant proteins were mixed and denatured/
–tricine gel was run, western blotted and probed with the antibodies as
eaction of the anti S100A9 antibody with S100A8 and vice versa.
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known. The most well-known one is the pathological form of
the prion protein (PrPSc). In contrast to S100A8/A9 prion pro-
tein is an integral membrane protein and is not considered as a
pathological protein. Several reports indicate that distinct ter-
tiary structures of S100A8 and S100A9 exist and that each or
some of them exert individual functions independent of the
preferred heterodimerisation [7–18]. Since most of these pro-
posed cellular functions take place in the extracellular environ-
ment, it is important to keep in mind that the proteins are
secreted from activated phagocytes at sites of inﬂammation
where a number of proteases are active either to remove debris
or associated with tissue remodelling [1]. Therefore, the diﬀer-
ential protease resistance may represent a physiologically sig-
niﬁcant regulatory mechanism controlling the functions of
the distinct tertiary structures of S100A8 and S100A9.
Similarly, S100A12 has been considered as RAGE ligand
triggering cellular activation and generation of proinﬂamma-
tory mediators [5]. Our ﬁnding indicates that the protease sen-
sitivity of S100A12 may restrict its function in a time and loci-
directed manner.
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